عنوان

Genome-based diagnostics :

شابک

0309253942

شابک

9780309253949

شماره

b510889

عنوان اصلي

Genome-based diagnostics :

نام عام مواد

[Book]

ساير اطلاعات عنواني

clarifying pathways to clinical use : workshop summary /

نام نخستين پديدآور

Steve Olson and Adam C. Berger, rapporteurs ; Roundtable on Translating Genomic-Based Research for Health, Board on Health Sciences Policy, Institute of Medicine of the National Academies

محل نشرو پخش و غیره

Washington, D.C. :

نام ناشر، پخش کننده و غيره

National Academies Press,

تاریخ نشرو بخش و غیره

[2012]

تاریخ نشرو بخش و غیره

©2012

نام خاص و کميت اثر

xx, 83 pages :

ساير جزييات

illustrations (some color) ;

ابعاد

23 cm

متن يادداشت

Includes bibliographical references (pages 61-62)

متن يادداشت

Introduction -- Calls for Change -- Test Developers -- Patients -- Payers --Regulation, Reimbursement, and Public Health -- Discussion of Major Proposals -- References -- Appendix A: Workshop Agenda -- Appendix B: Speaker Biographical Sketches -- Appendix C: Statement of Task-- Appendix D: Registered Attendees

بدون عنوان

0

متن يادداشت

"The sequencing of the human genome and the identification of associations between specific genetic variants and diseases have led to an explosion of genomic-based diagnostic tests. These tests have the potential to direct therapeutic interventions, predict risk or onset of disease, or detect residual disease. As research progresses and an increasing number of associations are found, further tests will be developed that can aid in providing personalized treatment options for patients. However, the adoption of genomic diagnostic tests by health care providers has been limited due to a lack of evidence regarding the clinical utility of many tests. Health funders and practitioners lack the data necessary to distinguish which tests can improve practice or the clinical settings in which tests will provide the greatest value. The Roundtable on Translating Genomic-Based Research for Health held a workshop in November 2010 to determine what evidence is needed and how it is viewed by different stakeholders in order to develop genomic diagnostic tests of clinical value. Genome-Based Diagnostics summarizes the presentations and discussions that took place throughout the workshop. Two presentations, in particular, sparked extensive discussion. One presentation proposed that all genomic diagnostic tests be reviewed and approved by the Food and Drug Administration. The other observed that venture capitalists are no longer investing substantially in the development of genomic diagnostic tests because of a lack of clarity surrounding regulatory and reimbursement pathways. Both presentations suggested the need for major changes in the systems used to develop, regulate, and reimburse genomic diagnostic tests. The report also presents the perspectives of different stakeholders in the development of genomic diagnostic tests. Each stakeholder group has a different set of needs and issues of importance, yet commonalities among them are apparent, such as the need to put patients and health outcomes at the center of discussion and action"--Publisher's description

موضوع مستند نشده

Genetic disorders

موضوع مستند نشده

Genetic disorders-- Diagnosis, Congresses

موضوع مستند نشده

Human chromosome abnormalities-- Diagnosis, Congresses

موضوع مستند نشده

Genetic Testing-- standards

موضوع مستند نشده

Genomics-- standards

موضوع مستند نشده

United States

بدون عنوان

2

مستند نام اشخاص تاييد نشده

Berger, Adam C

مستند نام اشخاص تاييد نشده

Olsen, Steven

مستند نام تنالگان تاييد نشده

Facilitating Development and Utilization of Genome-Based Diagnostic Technologies Workshop(2011 :, Washington, D.C.)

مستند نام تنالگان تاييد نشده

Institute of Medicine (U.S.)., Roundtable on Translating Genomic-Based Research for Health

تاريخ عمليات

20160203201040.0

نام الکترونيکي

نوع ماده

[Book]

تكميل شده

Y